Navigation Links
FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
Date:4/22/2013

irst-in-class chemical entities that boost the generation of new neurons. NSI-189, the first of these to be in a clinical trial, significantly stimulates the generation of new hippocampal neurons (neurogenesis) in vitro and in animal models.

NSI-189 is the lead compound in Neuralstem's neurogenic small molecule drug platform, which the company plans to develop into orally administered drugs for MDD and other psychiatric and cognitive disorders as diverse as traumatic brain injury, Alzheimer's disease, and PTSD. 

NSI-189 has been shown to stimulate neurogenesis of human hippocampus-derived neural stem cells in-vitro and in vivo. In healthy normal adult mice, NSI-189 stimulated neurogenesis in the hippocampus and significantly increased its volume, apparently by increasing its synaptic network after 28 days of daily oral administration. In mouse models of depression, NSI-189 significantly improved behavioral responses associated with depression. In humans, NSI-189 may reverse the human hippocampal atrophy seen in MDD and other disorders and reverse their symptoms. This program has received significant support from both the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH).

About the Trial

The NSI-189/MDD trial is a randomized, double-blind, placebo-controlled, multiple-dose escalating trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamic effect of NSI-189 in the treatment of MDD. Phase Ia, which  was completed in October 2011, tested escalating doses of single administration of NSI-189 in 41 healthy patients. Phase Ib is testing the safety of escalating doses of NSI-189 for 28 daily administrations in 24 depressed patients in three cohorts. This phase of the trial is expected to conclude in the third quarter of 2013.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
2. FDA Approves NDA Supported By MedAvante Central Ratings
3. Cardinal Health Board Of Directors Approves Cash Dividend; Authorizes New $750 Million Share Repurchase Program
4. Neuralstem Updates ALS Stem Cell Trial Progress
5. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
6. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
7. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
8. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
9. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
10. Neuralstem Announces Proposed Public Offering
11. Neuralstem to Raise $7.0 Million in Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  According to data released today ... 2015 average monthly Medicare Part D premium is expected ... than was originally projected, the Pharmaceutical Care Management Association ... continues to be a bright spot in American health ... each region and using cutting edge, cost-saving tools like ...
(Date:7/31/2014)... SAN DIEGO , July 31, 2014  Sorrento Therapeutics, ... death of Mr. Amar Singh , Chief Business Officer ... of apparent natural causes on July 30. "Sorrento ... dear friend and colleague. Our immediate thoughts go to Amar,s ... President and Chief Executive Officer. Mr. Singh ...
(Date:7/31/2014)... -- STAAR Surgical Company (NASDAQ: STAA ) ... and delivery systems for the eye today reported revenue ... $20.0 million, a 10% increase over $18.2 million reported ... currency basis, revenues grew 11% during the second quarter ... The effect of foreign currency exchange reduced sales by ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31
... 7 ActivBiotics, Inc. today,announced the results ... effect of rifalazil in the treatment of ... The results demonstrated,that treatment for two months ... in a significant improvement in walking distance,claudication ...
... the American Heart Association Scientific Sessions ... 2007 ... Nabi,Biopharmaceuticals (Nasdaq: NABI ) today announced the successful completion,of ... innovative and proprietary investigational vaccine being,developed to treat nicotine addiction ...
Cached Medicine Technology:Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 2Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 4Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 5Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 6Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 7
(Date:7/31/2014)... Leelanau Peninsula, MI (PRWEB) July 31, 2014 ... in preparation of the upcoming harvest. And, to celebrate, folks ... held Saturday and Sunday, September 6 and 7, 2014 along ... weekend festivities is an optional walk or run through the ... & Winery in Suttons Bay. A unique course between rows ...
(Date:7/31/2014)... July 31, 2014 Weblify has finally been ... years of development and testing. The result is a ... in as little as 5 minutes without knowing any HTML ... review , Shane Michaels, an SEO expert, agrees that this ... “I’ve seen a lot of web site builders out there, ...
(Date:7/31/2014)... United Theological Seminary is pleased to ... Donne and Peter J. Bellini. Both began their teaching ... is a Director of Non-Degree Programs, Mark Abbott, who ... Le Donne, Assistant Professor of New Testament, received a ... Testament, Second Temple Judaism, and Greek courses. His research ...
(Date:7/31/2014)... NEWwoodworks, fine woodworking group at ... presence with a website dedicated to highlighting their craft ... specialized in handcrafted cabinetry, furniture, stairs , doors, ... a reputation for taking on the remarkable, challenging projects ... craft with reclaimed wood, often using near extinct species ...
(Date:7/31/2014)... Ticket Down is a dependable source for authentic ... Sun Life Stadium in Miami on Monday, August 4th. ... and diehard soccer fans from the Miami, Florida area are ... Cup final in person at Sun Life Stadium. ... split into two groups where they will then play each ...
Breaking Medicine News(10 mins):Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3Health News:Growing Seminary Welcomes New Faculty 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 3Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 3
... Hospital Closures and Bankruptcies, PRINCETON, N.J., Nov. ... Association shows that U.S. hospitals enjoyed,healthy profits in ... hospitals,experienced an unprecedented rash of hospital bankruptcies and ... 2009 Edition, released last,week, the nation,s hospitals posted ...
... 2007; Gross Profit Percentage ... Increases from 45% to 50% of Revenue, IDAHO ... INIS) announces financial results for,the third quarter and nine-months ending ... period ended September 30, 2008,was $1,245,164 and $4,429,144 respectively as ...
... N.Y., Nov. 11 Misonix, Inc.,(Nasdaq: MSON ), ... which in Europe is used for the ablation ... today announced plans to,release first quarter fiscal year ... Michael A. McManus, President and Chief,Executive Officer and ...
... provides latest information to medical and investment ... ... of America, Inc.,(CPC) (OTC Bulletin Board: CPCF), today launched its new ... a wealth of information on the company and its investigational,product, MedClose(TM). ...
... colored labels for automated filling of ... sterile anesthesia syringes., ... of colored syringe labels to its Rapid-Fill(TM) Automated,Syringe Filler offering. ... efficient automation for IV syringe filling. The,system reduces pharmacy overhead ...
... and disinfect to minimize spread of germs, OMAHA, Neb., ... family and friends, it may also be a haven for ... Services to help,battle pesky germs before, during and after your ... soapy water. Place antibacterial,hand sanitizer in plain view for guests ...
Cached Medicine News:Health News:Nation's Hospitals Thrive as N.J. Facilities Struggle 2Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2008 Financial Results 2Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2008 Financial Results 3Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2008 Financial Results 4Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2008 Financial Results 5Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2008 Financial Results 6Health News:Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern 2Health News:CPC Launches New Web Site Highlighting Medical, Research and Technical Panel, MedClose(TM) VCS Animated Video 2Health News:CPC Launches New Web Site Highlighting Medical, Research and Technical Panel, MedClose(TM) VCS Animated Video 3Health News:Baxa Expands its Automated Syringe Processing Capabilities 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: